BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38004484)

  • 1. Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer.
    Gardani CFF; Pedrazza EL; Paz VS; Zanirati GG; da Costa JC; Andrejew R; Ulrich H; Scholl JN; Figueiró F; Rockenbach L; Morrone FB
    Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crowding within synaptic junctions influences the degradation of nucleotides by CD39 and CD73 ectonucleotidases.
    Rahmaninejad H; Pace T; Chun BJ; Kekenes-Huskey PM
    Biophys J; 2022 Jan; 121(2):309-318. PubMed ID: 34922916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Pretreatment CD4
    Turner RJ; Guy TV; Geraghty NJ; Splitt A; Watson D; Brungs D; Carolan MG; Miller AA; de Leon JF; Aghmesheh M; Sluyter R
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
    Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
    Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer.
    Ferreira JM; Matheus LHG; de Almeida RVS; Melo PAS; Leite KRM; Murta CB; Claro JFA; Camacho CP; Pontes-Júnior J; Dellê H
    Oncotarget; 2021 Aug; 12(16):1580-1586. PubMed ID: 34381563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD39 abrogates platelet-derived factors induced IL-1β expression in the human placenta.
    Forstner D; Guettler J; Brugger BA; Lyssy F; Neuper L; Daxboeck C; Cvirn G; Fuchs J; Kraeker K; Frolova A; Valdes DS; Stern C; Hirschmugl B; Fluhr H; Wadsack C; Huppertz B; Nonn O; Herse F; Gauster M
    Front Cell Dev Biol; 2023; 11():1183793. PubMed ID: 37325567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves.
    Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis.
    Fernández P; Perez-Aso M; Smith G; Wilder T; Trzaska S; Chiriboga L; Franks A; Robson SC; Cronstein BN; Chan ESL
    Am J Pathol; 2013 Dec; 183(6):1740-1746. PubMed ID: 24266925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction.
    Knight JS; Mazza LF; Yalavarthi S; Sule G; Ali RA; Hodgin JB; Kanthi Y; Pinsky DJ
    Front Immunol; 2018; 9():1322. PubMed ID: 29942314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine reduces viability, induces apoptosis, inhibits migration and modulates the CD39/CD73 axis in metastatic cutaneous melanoma cells.
    Manica D; da Silva GB; de Lima J; Cassol J; Dallagnol P; Narzetti RA; Moreno M; Bagatini MD
    Purinergic Signal; 2023 Sep; ():. PubMed ID: 37768408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
    Jacoberger-Foissac C; Cousineau I; Bareche Y; Allard D; Chrobak P; Allard B; Pommey S; Messaoudi N; McNicoll Y; Soucy G; Koseoglu S; Masia R; Lake AC; Seo H; Eeles CB; Rohatgi N; Robson SC; Turcotte S; Haibe-Kains B; Stagg J
    Cancer Immunol Res; 2023 Jan; 11(1):56-71. PubMed ID: 36409930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease.
    Kudryavtsev I; Serebriakova M; Zhiduleva E; Murtazalieva P; Titov V; Malashicheva A; Shishkova A; Semenova D; Irtyuga O; Isakov D; Mitrofanova L; Moiseeva O; Golovkin A
    Front Genet; 2019; 10():604. PubMed ID: 31402927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
    Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
    J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrolysis of ATP, ADP, and AMP is increased in blood plasma of prostate cancer patients.
    Gardani CFF; Cappellari AR; de Souza JB; da Silva BT; Engroff P; Moritz CEJ; Scholl JN; Battastini AMO; Figueiró F; Morrone FB
    Purinergic Signal; 2019 Mar; 15(1):95-105. PubMed ID: 30644036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between the Gene Expression of Adenosine Kinase Isoforms and the Expression of CD39 and CD73 Ectonucleotidases in Colorectal Cancer.
    Zhulai GA; Shibaev MI
    Acta Naturae; 2023; 15(2):42-49. PubMed ID: 37538807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression.
    Muñóz-Godínez R; de Lourdes Mora-García M; Weiss-Steider B; Montesinos-Montesinos JJ; Del Carmen Aguilar-Lemarroy A; García-Rocha R; Hernández-Montes J; Azucena Don-López C; Ávila-Ibarra LR; Torres-Pineda DB; Molina-Castillo G; Chacón-Salinas R; Vallejo-Castillo L; Pérez-Tapia SM; Monroy-García A
    Mediators Inflamm; 2020; 2020():1678780. PubMed ID: 33488292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional characterization of engineered bifunctional fusion proteins of CD39 and CD73 ectonucleotidases.
    Zhong EH; Ledderose C; De Andrade Mello P; Enjyoji K; Lunderberg JM; Junger W; Robson SC
    Am J Physiol Cell Physiol; 2021 Jan; 320(1):C15-C29. PubMed ID: 33052071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments.
    Gheler FV; Cappellari AR; Renck D; de Souza JB; de Melo RO; Moehlecke BZ; Moriguchi CA; Engroff P; Lambert APF; Rockenbach L; Morrone FB
    Mol Cell Biochem; 2021 Oct; 476(10):3719-3727. PubMed ID: 34089473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.